Interaction between Diclofenamide and Brinzolamide (ophthalmic)
Moderate
Synergy
| ID | DDInter540 and DDInter238 |
| Interaction | Following ophthalmic administration, brinzolamide and dorzolamide are systemically absorbed and may have additive pharmacologic effects with other, systemically administered carbonic anhydrase inhibitors. The risk of adverse effects such as drowsiness, paresthesia, tinnitus, electrolyte imbalance, metabolic acidosis, and gastrointestinal disturbances may be increased. |
| Management | The concomitant use of ocular and systemic carbonic anhydrase inhibitors is not recommended. |
| References | |
| Alternative for Diclofenamide |
G01A
Torasemide
Furosemide
Amphotericin B (lipid complex)
Dorzolamide (ophthalmic)
Sildenafil
Metronidazole (topical)
More
|
| Alternative for Brinzolamide (ophthalmic) |
S01E
Levobunolol (ophthalmic)
Physostigmine
Carbamoylcholine (ophthalmic)
Brimonidine (topical)
Epinephrine
Epinephrine (topical)
Physostigmine (ophthalmic)
Neostigmine
Tafluprost (ophthalmic)
Dipivefrin (ophthalmic)
Apraclonidine
More
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.